Clinical trials: Respiratory Syncytial Virus (RSV), open to volunteers
RSV Infection
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice.
- Trial name
- NCT06172660
- Testing
- Nirsevimab
- Where
- United States
- Volunteers
- 3,750 people
- Sponsor
- Yale University
Respiratory Syncytial Virus (RSV)
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults
This study is testing the safety and tolerability of a second dose of Respiratory Syncytial Virus Vaccine (RSVpreF) given approximately 5 years after the initial dose.
- Trial name
- NCT07885956
- Testing
- RSVpreF (Regimen A), RSVpreF (Regimen B)
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Pfizer
RSV Infection
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the…
- Trial name
- NCT06866405
- Testing
- RSVpreF
- Where
- 97 sites in United States, Argentina and 2 more
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV)
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised…
- Trial name
- NCT07768345
- Testing
- RSVpreF Vaccine
- Where
- 17 sites in United States
- Volunteers
- 440 people
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV), Respiratory Infection Virus
THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness
RSV is a leading cause of severe respiratory illness and hospitalisation for young children, with particularly high rates of RSV respiratory infection observed amongst Aboriginal and Torres Strait Islander children living in…
- Trial name
- THRIVE (NCT07578298)
- Testing
- Nirsevimab (RSV-specific monoclonal antibody)
- Where
- Australia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
Respiratory Syncytial Virus (RSV)
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
- Trial name
- NCT07653100
- Testing
- RSVpreF
- Where
- 13 sites in India
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV)
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to <18 years of age at high risk for RSV disease, including those who are immunocompromised.
- Trial name
- NCT07839871
- Testing
- RSVpreF
- Where
- 2 sites in United States, Japan
- Volunteers
- 920 people, healthy volunteers welcome
- Sponsor
- Pfizer
RSV Infection
The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation
Clesrovimab is an FDA-approved antibody drug recommended for infants younger than 8 months who are entering their first respiratory syncytial virus (RSV) season and whose mothers did not receive an RSV vaccine during pregnancy.
- Trial name
- NCT07824167
- Testing
- Clesrovimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Respiratory Syncytial Virus (RSV)
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
- Trial name
- NCT07694557
- Testing
- YKYY025 group
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Influenza Viruses, Respiratory Syncytial Virus (RSV)
ELderly REspiratory VIral Cohort
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and…
- Conditions
- Influenza Viruses, Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2, Human Metapneumovirus (hMPV)
- Trial name
- ELREVI (NCT07813481)
- Testing
- Respiratory viral infection
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Syncytial Virus (RSV)
Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
- Trial name
- NCT07807449
- Testing
- Recombinant RSV Vaccine (CHO Cell), Adjuvant Suspension, Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Yikang Biotech (Suzhou) Co., Ltd.
Respiratory Syncytial Virus (RSV)
A Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY018 for Inhalation Solution
A phase II clinical study to evaluate the efficacy and safety of YKYY018 for inhalation solution in adult participants with respiratory syncytial virus infection
- Trial name
- NCT07808268
- Testing
- YKYY018 for Inhalation Solution
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV)
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults
The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups
- Trial name
- NCT07764237
- Testing
- mRNA-1365 (Profile 2), mRNA-1345 (Profile 1), mRNA-1345 (Profile 3)
- Where
- 10 sites in Canada, United Kingdom
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Respiratory Tract Infections (RTI), Influenza -Like Illness
Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France
Every year in the fall and winter, numerous respiratory viruses (such as influenza viruses, SARS-CoV-2 (COVID-19), RSV, rhinovirus, and metapneumovirus) circulate in mainland France, causing acute respiratory infections (ARIs).
- Conditions
- Respiratory Tract Infections (RTI), Influenza -Like Illness, Influenza, COVID - 19
- Trial name
- RS-viro IRA (NCT07599449)
- Testing
- saliva sampling, Nasopharyngeal swab
- Where
- France
- Volunteers
- 25,000 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
RSV Infection, RSV
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and…
- Conditions
- RSV Infection, RSV, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT07482657
- Testing
- zelicapavir
- Where
- 8 sites in Thailand
- Volunteers
- 150 people
- Sponsor
- Enanta Pharmaceuticals, Inc
SARS CoV 2 Infection, RSV Infections
Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections
Respiratory viral infections caused by influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 remain major causes of morbidity, hospitalization, and mortality among older adults worldwide.
- Conditions
- SARS CoV 2 Infection, RSV Infections, Influenza Infection
- Trial name
- AIRE-INT (NCT07643688)
- Volunteers
- 150 people
- Sponsor
- Fabiana Sherine Ganem dos Santos
Respiratory Syncytial Virus (RSV)
A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
The purpose of this study is to elucidate the molecular mechanism by which novel adjuvants enhance the immunogenicity of Respiratory Syncytial Virus (RSV) vaccines by regulating antigen-specific B cell affinity maturation and T…
- Trial name
- NCT07618325
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
RSV Infections, RSV Immunisation
A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.
Respiratory syncytial virus (RSV) is a virus that often affects children during childhood. Even though most cases of RSV are mild, it can cause serious disease and even death - especially in very young babies, babies born too…
- Conditions
- RSV Infections, RSV Immunisation, Preterm Labour
- Trial name
- NCT06955728
- Testing
- Vaccine
- Where
- 11 sites in Ghana, Kenya and 2 more
- Volunteers
- 13,000 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to…
- Trial name
- NCT07516418
- Testing
- H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3
- Where
- 6 sites in Australia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi
Respiratory Syncytial Virus (RSV)
Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women
A Phase 1 study to evaluate safety, tolerability and immunogenicity a RSV vaccine in healthy women 18 to 49 years of age
- Trial name
- RSVVaccine (NCT07492706)
- Testing
- MKK900 60 µg, MKK900 120 µg, ABRYSVO®
- Where
- 2 sites in Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company